Topical alprostadil (Vitaros © ) in the treatment of erectile dysfunction after non-nerve-sparing robot-assisted radical prostatectomy

Abstract

Objective:

The aim of the study is the evaluation of the efficacy and safety of the treatment with topical alprostadil (Vitaros^©) in post-robot assisted radical prostatectomy (RARP) rehabilitation therapy of patients with erectile dysfunction (ED).

Methods:

Seventy-four patients were enrolled and underwent non-nerve-sparing RARP. Inclusion criteria: age <75, preoperatively International Index of Erectile Function (IIEF-5) >16, erection hardness score (EHS) ⩾2, weekly sexual intercourse ⩾1, affirmative answers to Sexual Encounter Profile Question (SEP-Q) 2 and SEP-Q3, Charlson Comorbidity Index (CCI) ⩽5, Eastern Cooperative Oncology Group (ECOG) performance status ⩽1, no moderate/severe cardiovascular disease.

Results:

Vitaros was administered ⩾2 twice a week. At month 6, the IIEF-5 decreased from 20.5 preoperative to 18.1 post-treatment. EHS score decreased from a mean of 3.3 to a mean of 3.0. The quality of life score decreased from an average of 5.1 to 2.3. Weekly sexual intercourse decreased from an average of 2.1 to 1.7. Six patients dropped out; 89.7% patients showed a positive SEP-Q2 and 77.8% a positive SEP-Q3. All patients responded positively to Global Assessment Questions (GAQ)-1 and 97% to GAQ-2. Of all 68 analyzed patients, 13 (17.6%) switched to intracavernous injection therapy.

Conclusions:

In conclusion, Vitaros may become a viable alternative to common injective therapies in well-selected patients after RARP.

Keywords

Alprostadil Erectile dysfunction Impotence Penile rehabilitation Prostatectomy Topical therapy

Get full access to this article

View all access options for this article.

References

Ficarra

Novara

Ahlering

et al . Systematic review and meta-analysis of studies reporting potency rates after robot-assisted radical prostatectomy. Eur Urol. 2012;62(3):418-430.

El-Sakka

. What is the current role of intracavernosal injection in management of erectile dysfunction? Int J Impot Res. 2016;28(3):88-95.

Hsing

Tsao

Devesa

. International trends and patterns of prostate cancer incidence and mortality. Int J Cancer. 2003;85:60.

McCullough

. Rehabilitation of erectile function following radical prostatectomy. Asian J Androl. 2008;10:61-74.

Wang

. Penile rehabilitation after radical prostatectomy: where do we stand and where are we going? J Sex Med. 2007;4(4 Pt 2):1085-1097.

Moreland

. Is there a role of hypoxemia in penile fibrosis: a viewpoint presented to the Society for the Study of Impotence. Int J Impot Res. 1998;10(2):113-120.

User

Hairston

Zelner

McKenna

McVary

. Penile weight and cell subtype specific changes in a post-radical prostatectomy model of erectile dysfunction. J Urol. 2003;169(3):1175-1179.

Leungwattanakij

Bivalacqua

Usta

et al . Cavernous neurotomy causes hypoxia and fibrosis in rat corpus cavernosum. J Androl. 2003;24(2):239-245.

Rogers

Trock

Walsh

. Preservation of accessory pudendal arteries during radical retropubic prostatectomy: surgical technique and results. Urology. 2004;64(1):148-151.

10.

Karakiewicz

Tanguay

Kattan

Elhilali

Aprikian

. Erectile and urinary dysfunction after radical prostatectomy for prostate cancer in Quebec: a population based study of 2415 men. Eur Urol. 2004;46:188-194.

11.

Latini

Penson

Lubeck

Wallace

Henning

Lue

. Longitudinal differences in disease specific quality of life in men with erectile dysfunction: results from the exploratory comprehensive evaluation of erectile dysfunction study. J Urol. 2003;169(4):1437-1442.

12.

Shabsigh

Padma-Nathan

Gittleman

McMurray

Kaufman

Goldstein

. Intracavernous alprostadil alfadex (EDEX/VIRIDAL) is effective and safe in patients with erectile dysfunction after failing sildenafil (Viagra). Urology. 2000;55(4):477-480.

13.

Yiou

Ebrahiminia

Mouracade

Lingombet

Abbou

. Sexual quality of life in women partnered with men using intracavernous alprostadil injections after radical prostatectomy. J Sex Med. 2013;10(5):1355-1362.

14.

Linet

Ogrinc

. Efficacy and safety of intracavernosal alprostadil in men with erectile dysfunction. The alprostadil Study Group. N Engl J Med. 1996;334(14):873-877.

15.

Porst

. The rationale for prostaglandin E1 in erectile failure: a survey of worldwide experience. J Urol. 1996;155(3):802-815.

16.

Lakin

Montague

VanderBrug Medendorp

Tesar

Schover

. Intracavernous injection therapy: analysis of results and complications. J Urol. 1990;143(6):1138-1141.

17.

Parisot

Yiou

Salomon

de la Taille

Lingombet

Audureau

. Erection hardness score for the evaluation of erectile dysfunction: further psychometric assessment in patients treated by intracavernous prostaglandins injections after radical prostatectomy. J Sex Med. 2014 Aug;11(8):2109-2118.

18.

Nelson

Choi

Mulhall

Roth

. (2007) Determinants of sexual satisfaction in men with prostate cancer. J Sex Med. 2007;4(5):1422-1427.

19.

Nelson

Deveci

Stasi

Scardino

Mulhall

. Sexual bother following radical prostatectomy. J Sex Med. 2010;7(1 Pt 1):129-135.

20.

Alkhateeb

Lawrentschuk

. (2011) Consumerism and its impact on robotic-assisted radical prostatectomy. BJU Int. 2011;108:1874-1878.

21.

Mulhall

. Penile length changes after radical prostatectomy. BJU Int. 2005;96:472-474.

22.

Magheli

Burnett

. Erectile dysfunction following prostatectomy: prevention and treatment. Nat Rev Urol. 2009;6:415-27.

23.

Kendirci

Bejma

Hellstrom

. Update on erectile dysfunction in prostate cancer patients. Curr Opin Urol. 2006;16(3):186-195.d8

24.

Becher

. Topical alprostadil cream for the treatment of erectile dysfunction. Expert Opin Pharmacother. 2004;5(3):623-632.

25.

Wolka

Rytting

Reed

Finnin

. The interaction of the penetration enhancer DDAIP with a phospholipid model membrane. Int J Pharm. 2004;271(1-2):5-10.

26.

McVary

Polepalle

Riggi

Pelham

. Topical prostaglandin E1 SEPA gel for the treatment of erectile dysfunction. J Urol. 1999;162(3 Pt 1):726-730.

27.

Yiou

Cunin

de la Taille

et al . Sexual rehabilitation and penile pain associated with intracavernous alprostadil after radical prostatectomy. J Sex Med. 2011;8(2):575-82.

28.

Gontero

Fontana

Bagnasacco

et al . Is there an optimal time for intracavernous prostaglandin E1 rehabilitation following non-nerve sparing radical prostatectomy? Results from a hemodynamic prospective study. J Urol. 2003 Jun;169(6):2166-2169

29.

Goldstein

Payton

Schechter

. A double-blind, placebo-controlled, efficacy and safety study of topical gel formulation of 1% alprostadil (Topiglan) for the in-office treatment of erectile dysfunction. Urology. 2001;57(2):301-305.

30.

Hakky

Baumgarten

Parker

et al . Penile rehabilitation: the evolutionary concept in the management of erectile dysfunction. Curr Urol Rep. 2014;15(4):393.